Welcome to our dedicated page for Regencell Bioscience Holdings SEC filings (Ticker: RGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Regencell Bioscience Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Regencell Bioscience Holdings's regulatory disclosures and financial reporting.
Regencell Bioscience Holdings Limited (RGC) filed a Form 6-K announcing a board change effective 30 June 2025.
- Appointment: Ms. Margaret Hoor Han Lo joins the board as an independent director and will sit on the audit, compensation, and nominating & corporate governance committees.
- Background: Ms. Lo brings 30+ years of real-estate investment experience and has no family ties to existing officers or directors.
- Resignation: Independent director Mr. Paul J. Niewiadomski resigned for personal reasons on the same date; he previously chaired the nominating & corporate governance committee and served on the audit and compensation committees.
- No disagreements: The company states the resignation was not due to any dispute over operations, policies, or practices. Mr. Niewiadomski will remain in an advisory capacity.
Other than the governance transition, the filing contains no financial or operational updates.
Regencell Bioscience Holdings Limited (RGC) filed a Form 6-K with the U.S. SEC for the month of June 2025. The submission is largely administrative in nature and furnishes, pursuant to Nasdaq Rule 5250(c)(2), the company’s unaudited condensed consolidated interim balance sheets and statements of operations and comprehensive loss for the six-month period ended 31 December 2024. These financial statements are provided as Exhibit 99.1, titled “Regencell Bioscience Holdings Limited Announces First Half 2025 Management Financial Results.” No detailed line-item financial data, earnings guidance, or strategic initiatives are included in the body of the filing. The document also contains standard signature and filing-cover information confirming that Regencell continues to file its annual reports on Form 20-F.
Because the actual financial tables are presented only in the attached exhibit and not within the filing text supplied, investors will need to review Exhibit 99.1 separately to evaluate revenue trends, profitability, liquidity, or other key performance indicators. Overall, the filing appears routine and does not announce any major transactions, capital raises, or changes in corporate governance.
FAQ
What is the current stock price of Regencell Bioscience Holdings (RGC)?
What is the market cap of Regencell Bioscience Holdings (RGC)?
